MARKET

LCI

LCI

Lannett Co
NYSE

Real-time Quotes | Nasdaq Last Sale

5.81
-0.27
-4.44%
Opening 15:58 09/23 EDT
OPEN
6.11
PREV CLOSE
6.08
HIGH
6.13
LOW
5.72
VOLUME
306.63K
TURNOVER
--
52 WEEK HIGH
14.72
52 WEEK LOW
4.890
MARKET CAP
233.68M
P/E (TTM)
-6.6705
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Lannett: Poor, Near-Term Prospect And Less Impressive, Long-Term Opportunities Than Initially Thought, Avoid This Stock
Lannett is facing its darkest hours. Q4 results confirm that things won’t be the same without Levo, even though the company has resigned a new deal.Meanwhile, gross margin and EBITDA will decline coming into FY2021. Recent product launches have been impressive in terms of quantity, but lack quality.Management quotes much lower potential revenues for the new Levo, Advair, and Insulin, all key drivers for the future of Lannett.The medium- to long-term period promises sizeable addressable market, but requires a leap of faith and patience, which the market doesn’t have much at the moment.We were bullish on Lannett before, but admit this is turning out to be our biggest mistake. Investors should avoid this stock.
Seekingalpha · 08/31 11:00
Lannett Company, Inc. (LCI) CEO Tim Crew on Q4 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/27 01:11
Lannett: Q4 Earnings Insights
Shares of Lannett (NYSE:LCI) moved lower by 7.6% in after-market trading after the company reported Q4 results.Quarterly Results Earnings per share fell 16.22% year over year to $0.31, which beat the estimate of $0.29.Revenue of $137,920,000 higher by 3.05% year over year, which beat the estimate of
Benzinga · 08/26 22:14
BOX, FLWS, SMTC and LCI among after-hours movers
Gainers: [[NTAP]] +8.8%. [[BOX]] +7.9%. [[RYTM]] +7.4%. [[KIRK]] +5.4%. [[FLWS]] +4.6%.Losers: [[EGLE]] -6.0%. [[WSM]] -5.9%. [[SMTC]] -5.4%. [[LCI]] -5.0%. [[LI]] -4.9%.
Seekingalpha · 08/26 21:49
Lannett FQ4 top line up 3% as benefits of restructuring take hold
Lannett Company (LCI) fiscal Q4 results:Net sales: $137.9M (+3.1%).Net loss: ($9.7M) (-27.6%); non-GAAP net income: $13.4M (-8.8%); loss/share: ($0.25) (-25.0%); non-GAAP EPS: $0.31 (-16.2%).Non-GAAP EBITDA: $35.2M.Cash balance increased by more
Seekingalpha · 08/26 20:38
Lannett EPS beats by $0.04, beats on revenue
Lannett (LCI): Q4 Non-GAAP EPS of $0.31 beats by $0.04; GAAP EPS of -$0.25 misses by $0.45.Revenue of $137.92M (+3.0% Y/Y) beats by $3.62M.Shares -2.48%.Press Release
Seekingalpha · 08/26 20:18
Notable earnings after Wednesday's close
[[BILI]], [[BOX]], [[ESTC]], [[GEF]], [[LCI]], [[NTAP]], [[SMTC]], [[SPLK]], [[WSM]]For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 08/25 21:35
Lannett FQ4 2020 Earnings Preview
Lannett (NYSE:LCI) is scheduled to announce FQ4 earnings results on Wednesday, August 26th, after market close. The consensus EPS Estimate is $0.27 (-27.0%
Seeking Alpha - Article · 08/25 21:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LCI. Analyze the recent business situations of Lannett Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LCI stock price target is 7.75 with a high estimate of 9.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 169
Institutional Holdings: 41.92M
% Owned: 104.22%
Shares Outstanding: 40.22M
TypeInstitutionsShares
Increased
53
3.13M
New
24
1.23M
Decreased
43
3.50M
Sold Out
25
1.40M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.55%
Pharmaceuticals & Medical Research
-1.30%
Key Executives
Chairman/Independent Director
Patrick LePore
Chief Executive Officer/Director
Timothy Crew
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
John Kozlowski
Chief Operating Officer/Vice President
John Abt
Senior Vice President
Maureen Cavanaugh
Vice President/Chief Information Officer
Robert Ehlinger
General Counsel
Samuel Israel
Director
Jeffrey Farber
Director
Albert Paonessa
Independent Director
John Chapman
Independent Director
David Drabik
Independent Director
Melissa Rewolinski
Independent Director
Paul Taveira
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LCI
Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Lannett Company, Inc. stock information, including NYSE:LCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCI stock methods without spending real money on the virtual paper trading platform.